佰仁医疗2025年业绩快报：归母净利润同比增长36.81%

Core Viewpoint - Beijing Bairen Medical Technology Co., Ltd. reported a strong performance for the year 2025, with significant revenue and profit growth driven by innovation and effective cost management [1] Financial Performance - The company achieved total operating revenue of 630 million yuan, representing a year-on-year increase of 25.60% [1] - The net profit attributable to shareholders reached 200 million yuan, reflecting a year-on-year growth of 36.81% [1] Operational Highlights - Bairen Medical leveraged its advantages in implant materials and device innovation, demonstrating resilience amid industry policy changes and competitive pressures [1] - The company maintained effective control over management and sales expenses while continuing to invest heavily in research and development [1] Research and Development - During the reporting period, the company made significant R&D progress, submitting 8 product registration applications and nearing completion of pre-registration preparations for 4 additional products [1] - The company received approval for 3 new products, including the transcatheter valve-in-valve and ePTFE pericardium, which fill gaps in the domestic market [1]